Novo Nordisk: ups sales view after nine-month update
(CercleFinance.com) - Danish drugmaker Novo Nordisk said on Friday that it was "very satisfied" with its sales growth during the first nine months of 2019, prompting a slight rise in the group's shares.
The company has raised its 2019 sales growth outlook to 5%-6% at constant exchange rates (CER), compared to 4-6% previously, while operating profit growth is still expected to be 4-6% at CER.
The world's biggest insulin producer said on Friday that sales increased by 5% at constant exchange rates to 89.6 billion Danish kronor (about 12 billion euros) in the first nine months of 2019.
Sales of obesity drugs jumped by 50% in particular, the group said.
Novo Nordisk's operating profit rose by 5% at constant exchange rates over the period, the group added.
The shares are currently up 1.8% at 372.7 Danish kronor on the Nasdaq Nordic market.
Copyright (c) 2019 CercleFinance.com. All rights reserved.